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A B S T R A C T
Palatable oral pharmaceuticals are crucial for feline medication. The pharmaceutical industry prefers synthetic
ﬂavours over organic ones because of hygiene and regulatory issues. The aim of this study was to ﬁnd a palatable
synthetic ﬂavour for future taste-masking of feline pharmaceuticals. The hypothesis was that synthetic meat
aromas and free amino acids would be palatable to cats. The palatability of 18 synthetically ﬂavoured mini-
tablets was screened with 10–19 pet cats using a rapid 3-portal acceptance test with and without food. The tested
ﬂavours were synthetic amino acids (L-carnitine, L-glutamic acid monosodium salt hydrate, L-leucine, L-me-
thionine, L-phenylalanine, L-proline, and taurine), D-(+)-Maltose monohydrate and thiamine hydrochloride.
Furthermore, thiamine hydrochloride was combined with amino acids (L-cysteine, L-leucine, L-methionine and L-
proline) and synthetic meat ﬂavours (2-acetylpyridine, 2-acetylthiazole, 2-pentylpyridine and 4-hydroxy-5-
methyl-3(2H)-furanone). The negative control was a non-ﬂavoured placebo mini-tablet, while positive controls
were an organic yeast-ﬂavoured mini-tablet and a yeast- and ﬁsh-based commercial vitamin tablet in mini-tablet
form. No signiﬁcant diﬀerences were detected between palatable synthetic ﬂavours and the placebo, nor be-
tween the synthetic ﬂavours and the yeast ﬂavour. In general, the mini-tablet seemed to be small enough to be
accepted inside a food item. These results diﬀer from the earlier literature about the taste preferences of cats for
amino acids, and hence free amino acids should not be considered palatable to cats based purely on previous
ﬁndings.
1. Introduction
Cats can be diﬃcult to medicate against their will (Thombre, 2004).
Forcing a cat to take a pill can lead to owner injuries and also have a
negative eﬀect on the cat-owner relationship. Most of the problems
concerning feline medication are related to unpleasant taste and many
of the oﬀ-label solid pharmaceuticals are too large in size for cats
(Sivén et al., 2016). Voluntary acceptance of the pharmaceutical would
likely increase the medication adherence in cats, and improve the
success of the treatment (Thombre, 2004). Hence, there is a need for
palatable and easily administered feline pharmaceuticals.
The most preferred ﬂavour would be synthetic, because organic
ﬂavours complicate the manufacturing process, and regulatory issues
for meat-based ﬂavours may also exist (Ahmed & Kasraian, 2002;
Thombre, 2004). However, cats can be selective over their food
(Bradshaw, Healey, Thorne, Macdonald, & Arden-Clark, 2000), and
therefore ﬁnding a palatable ﬂavour acceptable to most cats is
challenging.
In the literature reviewed, cats are widely considered to prefer
certain amino acids (Bradshaw, 1991; Bradshaw, Goodwin, Legrand-
Defrétin, & Nott, 1996; MacDonald, Rogers, & Morris, 1984; Thombre,
2004; Zaghini & Biagi, 2005). However, this information is based on old
neurophysiological studies in anesthetized cats, where the sensory ef-
fect of chemical substances was studied (Boudreau, 1974; Boudreau &
Alev, 1973), and preference studies carried out on laboratory cats
(Beauchamp, Maller, & Rogers, 1977; White & Boudreau, 1975). L-
proline, L-cysteine, L-ornithine, L-lysine, L-histidine and L-alanine trig-
gered a discharge in the amino acid units on the tongue of the cat, while
L-tryptophan, L-isoleucine, L-arginine and L-phenylalanine inhibited the
units (Boudreau, 1974; Boudreau & Alev, 1973). Interestingly, the
triggering amino acids have been described as ‘sweet’, and the in-
hibiting ones as ‘bitter’ by humans (Boudreau, Oravec, & White, 1981).
When tested as saline or water solutions, laboratory cats preferred L-
proline, L-lysine and L-histidine, and avoided L-tryptophan, L-isoleucine,
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adenine and L-glutamic acid, preferred or avoided L-alanine, and neither
preferred nor avoided glycine (Beauchamp et al., 1977; White &
Boudreau, 1975). Laboratory kittens chose food containing large
quantities of leucine (Hargrove, Morris, & Rogers, 1994). Various
methods have been used to assess the palatability of feline pharma-
ceuticals (Bernachon et al., 2014a; Bernachon, Fournel, Gatto,
Monginoux, & McGahie, 2014b; Cron, Zemirline, Beranger, & Privat,
2014; Giraudel, Gruet, Alexander, Seewald, & King, 2010; Gunew,
Menrath, & Marshall, 2008; Huhtinen et al., 2015; Khor et al., 2011;
Litster et al., 2007; Morton, Grant, Johnston, Letellier, & Narbe, 2011;
Traas et al., 2010) because a guideline on the demonstration of palat-
ability of veterinary medicinal products has only been published quite
recently by the European Medicines Agency (EMA, 2014).
The primary aim of our study was to ﬁnd a palatable synthetic
ﬂavour for future taste- masking of feline pharmaceuticals by screening
ﬂavours compressed into a mini-tablet form with a rapid 3-portal ac-
ceptance test on pet cats. Secondary aims were to evaluate the ac-
ceptability of a mini-tablet when concealed inside a palatable food
item, and to test the feasibility of an owner-performed 3-portal accep-
tance test carried out on pet cats in their home environment.
The hypotheses were that palatable ﬂavours for cats exist among the
tested ﬂavours, and that the size of a mini-tablet would be ideal when
administered inside a palatable food item. Other hypotheses were that a
commercial vitamin tablet and an organic yeast ﬂavour would be pa-
latable for cats in mini-tablet form.
2. Material and methods
The Research Ethics Committee of the University of Helsinki ap-
proved the study protocol on 18 November 2010.
2.1. Cats
A total of 23 adult cats belonging to 10 owners participated in the
seven trials. Ten cats were enrolled in most of the trials, but trial 3
included 19 cats (supplementary Table S1). Most of the cats were ca-
strated males (n=15), ﬁve cats were spayed females, two were intact
females and one was an intact male. The age of the cats varied from one
to 15 years at the time of the study, and most of the cats did not have
free access to outdoors, only four of the cats were able to go outdoors
freely. The owners were recruited among the students and personnel of
the Faculty of Veterinary Medicine at the University of Helsinki, as well
among their friends. No restrictions were placed on the age or breed of
the cats, or on the number of cats in the households. According to the
owners, the cats were healthy and had a normal appetite. Participation
was voluntary, and the owners did not receive any ﬁnancial induce-
ments. All of the owners signed consent forms.
2.2. Tested items
The synthetically ﬂavoured mini-tablets (25mg) consisted of the
tested ﬂavours and tablet excipients. They were round with a biconvex
shape and a diameter of 3mm. We also tested the acceptability of a non-
ﬂavoured mini-tablet (placebo), consisting of tablet excipients, inside a
food item. Positive controls comprised an organic yeast-ﬂavoured mini-
tablet (Yeast Extract, AppliChem) and a commercial vitamin tablet
(Kitzyme, Bob Martin) in mini-tablet form. The commercial vitamin
tablet was also tested in its original form to ensure the acceptable
mouthfeel of the mini-tablet. The ingredients and the manufacturers are
listed in Table 1, and the compositions of the mini-tablets in Table 2.
2.3. Study design
The owners were blinded to the tested items, and the mini-tablets
were oﬀered in a random order to the cat, with the exception of trial 5,
where only one mini-tablet was tested. The mini-tablets were packed in
small transparent plastic bags. The bags were numbered manually with
a pen, and the tablets were tested in numerical order.
The trials were carried out in the home environments of the cats by
the owners, and the researchers were not present in the test situation.
The owners were instructed in writing about the study protocol and to
perform the palatability trials when the cat was cooperative and alert. A
table was recommended as a suitable testing area. The type of food was
chosen by the owners based on the individual taste preferences of each
cat. The food item was supposed to be small enough to be eaten at one
go (supplementary Table S1). The cats were familiarized with the test
situation by oﬀering food on the table. To standardize the hunger status
of the cats, they were not fed for at least six hours before the trial or, if
fed ad libitum, overnight. The cats were not forced to participate in the
trials; they were lifted onto the table if necessary, after which they were
free to choose their actions.
The mini-tablets were tested by using a rapid 3-portal acceptance
test as follows: ﬁrst, the cat was oﬀered the mini-tablet on the table. If
the cat did not notice the mini-tablet, the owner pointed to it with a
ﬁnger. If the cat did not eat the mini-tablet (ate: yes/no), it was then
oﬀered by hand, holding it between two ﬁngers, so that the cat could
sniﬀ the tablet. If the cat did not accept the tablet (ate: yes/no), it was
ﬁnally provided by concealing it in the palatable food item (ate: yes/
no). The owners were also able to write down comments.
In most trials, only one mini-tablet was tested per day, but if the cat
was cooperative, one or two mini-tablets could be tested on the same
day in trial 3 (Table 2), and in trial 1 three similar placebo mini-tablets
were tested on the same or consecutive days, and only inside a palatable
food item.
2.4. Statistical methods
Due to the low number of cats, the analysis was mainly descriptive.
One-way frequency tables were generated for each mini-tablet type:
synthetic ﬂavours, positive controls and placebo (Table 3). The syn-
thetically ﬂavoured mini-tablets and the two controls (the yeast-ﬂa-
voured and the commercial vitamin-ﬂavoured mini-tablets) were
compared descriptively with cross tabulations. Dichotomized variables
were used for cross tabulations of the synthetic ﬂavours against the
Table 1





Mannitol (Pearlitol 160 C) Roquette, France
Hydroxypropyl cellulose Sodium
stearyl fumarate (Pruv)





Flavour L-carnitine Sigma-Aldrich, USA
L-cysteine Sigma-Aldrich, Japan








Thiamine hydrochloride Hawkins Inc., USA







Yeast extract AppliChem, Germany
Vitamin tablet Commercial vitamin tablet for
cats (Kitzyme)
Bob Martin, UK
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placebo (ate vs. did not eat the tablet). The synthetically ﬂavoured
mini-tablets were compared with the yeast-ﬂavoured and the com-
mercial vitamin-ﬂavoured mini-tablets using Wilcoxon signed-rank
tests. All statistical analyses were performed using SAS System for
Windows, version 9.3 (SAS Institute Inc., Cary, NC, USA). P≤ 0.05 was
considered to be statistically signiﬁcant, and P > 0.05 to P≤ 0.10 was
considered to show a tendency.
3. Results
The acceptance of each ﬂavoured mini-tablet is presented in
Table 3. No synthetic ﬂavour was signiﬁcantly more acceptable than
the placebo mini-tablet when administered inside a food item. No sta-
tistically signiﬁcant diﬀerences were detected between the synthetic-
ﬂavoured mini-tablets and the yeast-ﬂavoured mini-tablet, but the
commercial vitamin-ﬂavoured mini-tablet tended to be more palatable
than most of the synthetically ﬂavoured mini-tablets (P=0.0625). The
same ﬁve cats ate the commercial vitamin-ﬂavoured mini-tablets and
the original commercial vitamin tablets, while the other ﬁve cats ate
neither of them.
While cats did not eat the synthetically ﬂavoured mini-tablets
without food, the owners commented that some of the cats showed
interest towards them (Table 3). One owner commented that the size of
the mini-tablet was optimal. Another mentioned that the small-sized
tablet might be diﬃcult for the cat to notice. One owner wrote that the
mini-tablet stuck to the cat's nose while the cat was sniﬃng it. The
owners commented in trial 3 that one cat was not motivated by the
food, while another was used to receiving treats by hand. In trial 6, four
cats were not motivated by the food in some of the tests. One owner
stated that her cat ate the L-carnitine mini-tablet from the table, but
vomited immediately and showed signs of short-term nausea. No other
side eﬀects were observed during the trials.
4. Discussion
The original purpose of this study was to rapidly screen the ac-
ceptability of several synthetic ﬂavours pending further testing with
preference tests to ﬁnd the most palatable ﬂavour for the taste- masking
of feline pharmaceuticals. The main ﬁnding was that amino acids did
not prove to be palatable to cats, which contradicted the previous
studies (Beauchamp et al., 1977; Boudreau, 1974; Boudreau & Alev,
1973; White & Boudreau, 1975). Although the number of cats tested
Table 2
Trial number, number of cats, ﬂavours of tested mini-tablets and tablet composition.
Trial number Number of tested
cats
Tablet ﬂavour(s) and amount in tablet composition (% m/m) Tablet excipient(s) and amount in tablet
composition (% m/m)
1 10 Non-ﬂavoured placebo Microcrystalline cellulose (Avicel PH 101)
(70%m/m)
Mannitol (Pearlitol 160C) (25%m/m)
Hydroxypropyl cellulose (5%m/m)
Sodium stearyl fumarate (Pruv) (1%m/m)
2 10 L-glutamic acid monosodium salt hydrate, 50%m/m Microcrystalline cellulose (Emcocel LP200),
50%m/m
L-leucine, 50%m/m Microcrystalline cellulose (Emcocel LP200),
50%m/m
L-methionine, 50%m/m Microcrystalline cellulose (Emcocel LP200),
50%m/m
L-phenylalanine, 50%m/m Microcrystalline cellulose (Emcocel LP200),
50%m/m
L-proline, 50%m/m Microcrystalline cellulose (Emcocel LP200),
50%m/m
Thiamine hydrochloride, 50%m/m Microcrystalline cellulose (Emcocel LP200),
50%m/m
3 19 Thiamine hydrochloride, 50%m/m Microcrystalline cellulose (Emcocel LP200),
50%m/m
Thiamine hydrochloride - L-cysteine, 50%m/m of ﬂavour 1:1 mixture Microcrystalline cellulose (Emcocel LP200),
50%m/m
Thiamine hydrochloride - L-leucine, 50%m/m of ﬂavour 1:1 mixture Microcrystalline cellulose (Emcocel LP200),
50%m/m
Thiamine hydrochloride - L-methionine, 50%m/m of ﬂavour 1:1 mixture Microcrystalline cellulose (Emcocel LP200),
50%m/m
Thiamine hydrochloride -L-proline, 50%m/m of ﬂavour 1:1 mixture Microcrystalline cellulose (Emcocel LP200),
50%m/m
4 10 L-carnitine, 50%m/m Microcrystalline cellulose (Emcocel LP200),
50%m/m
Taurine, 50%m/m Microcrystalline cellulose (Emcocel LP200),
50%m/m
5 10 D-(+)-maltose monohydrate, 50%m/m Microcrystalline cellulose (Emcocel LP200),
50%m/m
6 10 2-acetylthiazole, 2%m/m Microcrystalline cellulose (Emcocel LP200),
98%m/m
2-acetylpyridine, 2%m/m Microcrystalline cellulose (Emcocel LP200),
98%m/m
4‑hydroxy-5-methyl-3(2H)-furanone, 2%m/m Microcrystalline cellulose (Emcocel LP200),
98%m/m
2-pentylpyridine, 2%m/m Microcrystalline cellulose (Emcocel LP200),
98%m/m
7 10 Yeast extract, 50%m/m Microcrystalline cellulose (Emcocel LP200),
50%m/m
Commercial vitamin tablet (Kitzyme, Bob Martin, UK) in mini-tablets containing the
following ingredients: dried brewer's yeast, vegetable protein, dicalcium phosphate,
encapsulated ﬁsh oil, calcium carbonate, silicon dioxide, magnesium stearate, ﬁsh powder
-
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was low, the results seemed evident: most of the cats did not voluntarily
accept the synthetically ﬂavoured mini-tablets without them being
concealed inside a palatable food item. On the other hand, the mini-
tablet form appeared ideal for concealment in a food item, and its
mouthfeel seemed to be acceptable to the cats. Furthermore, we ob-
served that owner-perceived palatability trials carried out on pet cats in
their home environments could be used for testing the palatability of
pharmaceuticals for cats.
Amino acids were chosen for test purposes because of the carni-
vorous nature of cats, as amino acids are precursors of meat. In our
study, most of the cats did not voluntarily accept the tested amino acids
without food. Even though we did not test the palatability of the same
quantity of amino acids as in earlier studies, our results suggest that free
amino acids should not be claimed to be palatable to cats based solely
on previous studies without further palatability testing.
Thiamine hydrochloride is a major component of yeast, and also a
meat ﬂavour precursor (Varavinit, Shobsngob, Bhidyachakorawat, &
Subhantrika, 2000). Overall, most of the cats ate these ﬂavoured mini-
tablets only when concealed in a palatable food item. Thiamine tastes
bitter to humans (Stacey & Sullivan, 2003), and cats are very sensitive
to bitter taste (Lei et al., 2015), which may explain the low voluntary
acceptance of thiamine and its combinations with amino acids. Ap-
proximately 25% of the cats showed interest towards the mini-tablet of
thiamine hydrochloride combined with L-cysteine, a meat ﬂavour pre-
cursor (Varavinit et al., 2000), by licking it. However, this cannot ne-
cessarily be construed as a positive reaction, because licking food has
been related to a less palatable taste (Van den Bos, Meijer, & Spruijt,
2000). Unfortunately, we did not test the palatability of L-cysteine
alone.
D-(+)-Maltose monohydrate is the predominant sugar in malt ex-
tract, which is commonly used in Cat Malt products as an appetite
stimulant. However, it was not found to be palatable in our trial. On the
other hand, it is detected through T1R2 and T1R3 sweet taste receptors
(Pullicin, Penner, & Lim, 2017), and cats genetically lack the functional
T1R2 receptor (Li et al., 2005).
None of the cats consumed the synthetic meat-ﬂavoured mini-ta-
blets without them being concealed inside a food item, and some did
not eat them even when concealed in this way. Possibly their smell,
taste or both were unpleasant, but on the other hand, according to the
owners, some of the cats were not motivated to eat even the palatable
food. Some unspeciﬁed synthetic meat ﬂavours have been used in feline
pharmaceuticals, which did not have complete voluntary consumption
success either (Bernachon et al., 2014a; Huhtinen et al., 2015).
Microcrystalline cellulose was chosen for excipient of the mini-ta-
blets based on that it is harmless to cats, and also it is considered to be
tasteless to humans (Ejikeme, 2008), but this is not veriﬁed in cats.
Most of the ﬂavoured mini-tablets consisted of 50% of the ﬂavour and
50% of microcrystalline cellulose, but the synthetic meat ﬂavours had a
very strong aroma even to the human nose, and therefore synthetic
meat-ﬂavoured mini-tablets consisted of 2% of the ﬂavour and 98% of
microcrystalline cellulose to reduce the strong aroma.
The small-sized mini-tablets were generally well accepted when
concealed inside a palatable food item. However, as the food was not
standardized, the mini-tablets may have dropped out of some food
types more easily. In our previous study, the cats dropped a food item
containing a similar mini-tablet signiﬁcantly more often than food
without the tablet (Savolainen et al., 2016). It would be recommend-
able, therefore, to use standardized food to prevent the consistency of
the food from having an impact. However, the acceptability of the food
should be veriﬁed before the trials. It is possible that the food was not
palatable enough because some owners mentioned that the cat did not
eat the food in every test.
Table 3
Acceptance and interest towards each ﬂavoured mini-tablet separately. NT=not tested.
Flavoured mini-tablet Ate the tablet from
the table n (%)
Ate the tablet
from hand n (%)
Ate the tablet concealed
inside a food itemn (%)
Did not eat the
tablet at all n (%)
Took the tablet into the
mouth and dropped it n (%)
Licked the
tablet n (%)
Placeboa,b NT NT 8 (88.9) 1 (11.1) NT NT
L-glutamic acid monosodium salt
hydrate
0 (0.00) 0 (0.00) 9 (90.0) 1 (10.0) 0 (0.00) 0 (0.00)
L-leucine 0 (0.00) 1 (10.0) 8 (80.0) 1 (10.0) 0 (0.00) 0 (0.00)
L-methionine 0 (0.00) 0 (0.00) 9 (90.0) 1 (10.0) 1 (10.0) 0 (0.00)
L-phenylalaninec 0 (0.00) 0 (0.00) 8 (88.9) 1 (11.1) 0 (0.00) 0 (0.00)
L-proline 0 (0.00) 0 (0.00) 8 (80.0) 2 (20.0) 1 (10.0) 1 (10.0)
Thiamine hydrochlorided 0 (0.00) 0 (0.00) 8 (88.9) 1 (11.1) 2 (22.2) 1 (11.1)
Thiamine hydrochloride 1 (5.30) 1 (5.30) 14 (73.7) 3 (15.8) 3 (15.8) 3 (15.8.)
Thiamine hydrochloride - L-
cysteine
1 (5.30) 1 (5.30) 14 (73.7) 3 (15.8) 0 (0.00) 5 (26.3)
Thiamine hydrochloride - L-leucine 0 (0.00) 2 (10.5) 13 (68.4) 4 (21.1) 3 (15.8) 0 (0.00)
Thiamine hydrochloride - L-
methionine
1 (5.30) 0 (0.00) 16 (84.2) 2 (10.5) 1 (5.30) 0 (0.00)
Thiamine hydrochloride - L-proline 2 (10.5) 0 (0.00) 15 (78.9) 2 (10.5) 1 (5.30) 0 (0.00)
L-carnitine 1 (10.0) 0 (0.00) 9 (90.0) 0 (0.00) 0 (0.00) 0 (0.00)
Taurine 0 (0.00) 0 (0.00) 9 (90.0) 1 (10.0) 0 (0.00) 0 (0.00)
d-(+)-Maltose monohydrate 0 (0.00) 0 (0.00) 9 (90.0) 1 (10.0) 0 (0.00) 0 (0.00)
2-acetylthiazole 0 (0.00) 0 (0.00) 7 (70.0) 3 (30.0) 0 (0.00) 0 (0.00)
2-acetylpyridine 0 (0.00) 0 (0.00) 6 (60.0) 4 (40.0) 0 (0.00) 1 (10.0)
4‑hydroxy-5-methyl-3(2H)-
furanone
0 (0.00) 0 (0.00) 7 (70.0) 3 (30.0) 0 (0.00) 1 (10.0)
2-pentylpyridine 0 (0.00) 0 (0.00) 5 (50.0) 5 (50.0) 0 (0.00) 0 (0.00)
Commercial vitamin tablet,
originale
5 (50.0) 0 (0.00) NT 5 (50.0) 0 (0.00) 0 (0.00)
Commercial vitamin tablet, mini-
tablet
5 (50.0) 0 (0.00) 5 (50.0) 0 (0.00) 0 (0.00) 0 (0.00)
Yeast extract 4 (40.0) 0 (0.00) 6 (60.0) 0 (0.00) 1 (10.0) 2 (20.0)
a Tested three times, only concealed inside a food item.
b One cat excluded because of discrepancy between results of the three trials (ate once with a food item).
c Tested twice on the same cat because of owner confusion.
d Tested twice on the same cat because of owner confusion.
e Tested without a food item.
S. Savolainen, et al. Veterinary and Animal Science 7 (2019) 100054
4
According to the EMA guideline (EMA, 2014), a pharmaceutical can
be claimed to be palatable if at least 70% of cats eat it voluntarily
without food; hence, the ﬂavoured mini-tablets could not be considered
palatable to the cats, not even in the case of our positive controls. In our
trials, a few cats took the mini-tablet into their mouth but dropped it,
and some cats licked it without eating it. In one palatability study of
anti-parasitic drugs carried out on laboratory cats, prehension from a
bowl or hand was assessed in addition to consuming the product
(Bernachon et al., 2014a). Prehension was deﬁned as the cat voluntarily
taking the tablet into their mouth, even if it was not swallowed. The
researchers discovered high prehension numbers in adult cats com-
pared to our pet cats, but the consumption was much lower
(Bernachon et al., 2014a). However, the behaviour and taste pre-
ferences of pet and laboratory cat populations diﬀer (Bradshaw et al.,
2000). Pet cats live in more enriched environments compared to la-
boratory cats, and also eat a more varied diet (Laﬂamme et al., 2008).
The cats in our study had variation in their sex, age and breed, and
also in their lifestyles as four of them had also access to go freely out-
doors. On the other hand, despite of the high individual variation, using
pet cats is consistent with the EMA guideline (EMA, 2014) for carrying
out palatability tests for pharmaceuticals on companion animals with
the target population. Some palatability assessments of pharmaceuticals
have been conducted on client-owned pet cats (Giraudel et al., 2010;
Gunew et al., 2008; Huhtinen et al., 2015; Litster et al., 2007; Morton
et al., 2011), and others on laboratory cats (Bernachon et al., 2014a;
Bernachon et al., 2014b; Cron et al., 2014). Cats may have a timid
nature and a fear of strangers or unfamiliar environments, and therefore
owner-performed palatability testing would help to avoid stress, and
thereby obtain more reliable results. However, care should be taken
that owners are well instructed before the trial. In our study, most of the
owners followed the instructions correctly. Tests carried out by the
owner could also be recorded with a video camera for later analysis, as
we did in our previous study in the feeding situation (Savolainen et al.,
2016). In our trials, the palatability was evaluated by the voluntary
acceptance of the mini-tablet. In previous studies, the voluntary ac-
ceptance test has been used either without food (Bernachon et al.,
2014a; Cron et al., 2014), with or without food (Bernachon et al.,
2014b; Huhtinen et al., 2015), or with food (Gunew et al., 2008). De-
spite the possible food eﬀects on the bioavailability of the pharma-
ceutical (Ahmed & Kasraian, 2002), the voluntary acceptance of a
pharmaceutical mixed with food is an animal-friendly administration
method. However, the product should not be claimed to be palatable if
it is accepted only with food, but should rather be deﬁned as ‘accep-
table with food’, for example.
We did not have any strict inclusion or exclusion criteria for the cats
in this study, in contrast to a study about feeding behaviour assessed by
observers where outgoing cat personalities were selected to avoid stress
(Van den Bos et al., 2000). Without strict exclusion criteria, a more
realistic target population is acquired. The only inclusion criteria in our
study were that the cat had a normal appetite and was clinically
healthy, according to the owner. However, in hindsight, we should have
instructed the owner not to continue the trial if the cat was not moti-
vated to eat the food that was oﬀered. Furthermore, it would have been
clearer if the same cats had been used in every trial, particularly in view
of the individual taste preferences of the cats.
A few owners submitted comments on the administration of the
mini-tablets. For example, a mini-tablet sticking to the cat's nose might
reduce the voluntary acceptance even if the mini-tablet was palatable,
as cats choose their food based on smell in the ﬁrst instance
(Hullár, Fekete, Andrásofsky, Szöcs, & Berkényi, 2001). Presumably,
this could be avoided by oﬀering the mini-tablet by hand. The reason
for vomiting after eating the L-carnitine mini-tablet could be related to
its unpleasant taste, because no other cat voluntarily accepted it
without food. Although not mentioned by the owners, the mini-tablets
might be diﬃcult to handle, for example by people with impaired vision
or large hands, which might be avoided if a suitable administration
device were developed. Moreover, in some cases, the mini-tablet might
also be too small to contain an adequate amount of the active drug
ingredient, whereupon several tablets would be needed for the proper
dosage.
Owner-perceived palatability trials carried out on pet cats in their
home environments could be used for testing the palatability of phar-
maceuticals for cats. However, due to the heterogenic population, the
number of cats should be higher than used in our study (EMA, 2014).
Furthermore, the cats should be motivated to eat in each trial, and the
owners should be well-instructed. If food is used for concealing the
tablet, the foodstuﬀ should be standardized and its palatability veriﬁed
for each particular cat before the trials. In addition, testing pharma-
ceuticals in healthy privately owned cats considers an ethical aspect
which should be severely considered. Pharmaceuticals tested should not
be harmful to the cats.
5. Conclusions
Synthetic ﬂavours did not improve the voluntary acceptance of the
mini-tablets that were not accepted without food by most of the cats.
Hence, the results did not support the earlier literature about amino
acids being palatable to cats. The size of the mini-tablet was optimal
when concealed inside a food item, and the mouthfeel of the mini-
tablet also seemed to be acceptable. The owner-performed palatability
tests carried out on pet cats in their home environments could be a
feasible method for testing the palatability of pharmaceuticals in cats.
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